D 5410
Latest Information Update: 06 May 1998
Price :
$50 *
At a glance
- Originator Celltech Group
- Class Antirheumatics
- Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 06 May 1998 Discontinued-Preclinical for Inflammatory bowel disease in United Kingdom (Unknown route)
- 22 Oct 1997 Discontinued-I for Osteoarthritis in United Kingdom (PO)
- 22 Oct 1997 Discontinued-I for Rheumatoid arthritis in United Kingdom (PO)